| Year |
Citation |
Score |
| 2024 |
Pan A, Bailey CC, Ou T, Xu J, Liu X, Hu B, Crynen G, Skamangas N, Bronkema N, Tran M, Mu H, Zhang X, Yin Y, Alpert MD, He W, et al. affinity maturation of the HIV-1 Env-binding domain of CD4. Research Square. PMID 38405717 DOI: 10.21203/rs.3.rs-3922904/v1 |
0.386 |
|
| 2024 |
Pan A, Bailey CC, Ou T, Xu J, Liu X, Hu B, Crynen G, Skamangas N, Bronkema N, Tran M, Mu H, Zhang X, Yin Y, Alpert MD, He W, et al. affinity maturation of the HIV-1 Env-binding domain of CD4. Biorxiv : the Preprint Server For Biology. PMID 38370774 DOI: 10.1101/2024.02.03.578630 |
0.386 |
|
| 2023 |
Callaway HM, Hastie KM, Schendel SL, Li H, Yu X, Shek J, Buck T, Hui S, Bedinger D, Troup C, Dennison SM, Li K, Alpert MD, Bailey CC, Benzeno S, et al. Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. Cell Reports. 42: 112014. PMID 36681898 DOI: 10.1016/j.celrep.2023.112014 |
0.374 |
|
| 2015 |
Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 519: 87-91. PMID 25707797 DOI: 10.1038/Nature14264 |
0.552 |
|
| 2014 |
Li Q, Zeng M, Duan L, Voss JE, Smith AJ, Pambuccian S, Shang L, Wietgrefe S, Southern PJ, Reilly CS, Skinner PJ, Zupancic ML, Carlis JV, Piatak M, Waterman D, ... ... Alpert MD, et al. Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. Journal of Immunology (Baltimore, Md. : 1950). 193: 3113-25. PMID 25135832 DOI: 10.4049/Jimmunol.1400820 |
0.514 |
|
| 2014 |
Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, ... ... Alpert MD, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. The Journal of Clinical Investigation. 124: 3879-90. PMID 25105367 DOI: 10.1172/Jci75539 |
0.522 |
|
| 2014 |
Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine. 6: 228ra39. PMID 24648342 DOI: 10.1126/Scitranslmed.3007730 |
0.585 |
|
| 2012 |
Alpert MD, Heyer LN, Williams DE, Harvey JD, Greenough T, Allhorn M, Evans DT. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. Journal of Virology. 86: 12039-52. PMID 22933282 DOI: 10.1128/Jvi.01650-12 |
0.57 |
|
| 2012 |
Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. Plos Pathogens. 8: e1002890. PMID 22927823 DOI: 10.1371/Journal.Ppat.1002890 |
0.556 |
|
| 2012 |
Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. Journal of Virology. 86: 11521-32. PMID 22896626 DOI: 10.1128/Jvi.01023-12 |
0.57 |
|
| 2012 |
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, ... ... Alpert MD, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England Journal of Medicine. 366: 1275-86. PMID 22475592 DOI: 10.1056/Nejmoa1113425 |
0.574 |
|
| 2012 |
Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. Journal of Virology. 86: 6189-96. PMID 22457527 DOI: 10.1128/Jvi.00491-12 |
0.602 |
|
| 2011 |
Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, Poignard P, Hessell AJ, Burton DR. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. Journal of Virology. 85: 10572-81. PMID 21849450 DOI: 10.1128/Jvi.05541-11 |
0.546 |
|
| 2010 |
Alpert MD, Rahmberg AR, Neidermyer W, Ng SK, Carville A, Camp JV, Wilson RL, Piatak M, Mansfield KG, Li W, Miller CJ, Lifson JD, Kozlowski PA, Evans DT. Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge. Journal of Virology. 84: 10748-64. PMID 20702641 DOI: 10.1128/Jvi.00945-10 |
0.495 |
|
| Show low-probability matches. |